en <span style=font-size:11pt><span style=line-height:normal><span style=font-family:Calibri,sans-serif><b><span style=font-size:10.0pt><span style=font-family:Cambria,serif><span style=color:#4472c4>Aims:</span></span></span></b><span style=font-size:10.0pt><span style=font-family:Cambria,serif> Heart failure reduced ejection fraction (HFrEF) is defined as symptoms, such as shortness of breath and edema with an ejection fraction of less than 40% in echocardiography. Regarding the pathogenesis, the role of inflammation is undeniable. Interleukin 6 (IL-6) is one of the pro-inflammatory cytokines that is important in cardiovascular disease and has a critical role in CAD. It is also related to complications caused by heart failure and mortality. Nanocurcumin is a polyphenol extracted from the rhizome of <i>Curcuma longa</i> (turmeric) with better bioavailability. Effects of nanocurcumin on the reduction of IL-6 and NT-proBNP in hospitalized HFrEF patients with acute </span></span><span style=font-size:10.0pt><span style=background:white><span style=font-family:Cambria,serif>decompensation </span></span></span><span style=font-size:10.0pt><span style=font-family:Cambria,serif>were investigated.</span></span></span></span></span><br> <span style=font-size:11pt><span style=line-height:normal><span style=font-family:Calibri,sans-serif><b><span style=font-size:10.0pt><span style=font-family:Cambria,serif><span style=color:#4472c4>Materials & Methods:</span></span></span></b><span style=font-size:10.0pt><span style=font-family:Cambria,serif> Sixty patients with HFrEF admitted with acute heart failure were divided into the intervention group with the administration of 40 mg of nanocurcumin twice a day for seven days and the control group (placebo). The levels of electrolytes, creatinine, IL-6, and NT-proBNP were measured at baseline and after one week.</span></span></span></span></span><br> <span style=font-size:11pt><span style=line-height:normal><span style=font-family:Calibri,sans-serif><b><span style=font-size:10.0pt><span style=font-family:Cambria,serif><span style=color:#4472c4>Findings:</span></span></span></b><span style=font-size:10.0pt><span style=font-family:Cambria,serif> There was no statistically significant difference in the reduction in IL-6 and NT-proBNP levels in the intervention and control groups (p>0.05). Also, there was no significant difference in creatinine and</span></span> <span style=font-size:10.0pt><span style=font-family:Cambria,serif>estimated glomerular filtration rate in the two groups (p>0.05).</span></span></span></span></span><br> <span style=font-size:11pt><span style=line-height:normal><span style=font-family:Calibri,sans-serif><b><span style=font-size:10.0pt><span style=font-family:Cambria,serif><span style=color:#4472c4>Conclusion:</span></span></span></b><span style=font-size:10.0pt><span style=font-family:Cambria,serif> Nanocurcumin at a dose of 40 mg twice a day for seven days in patients with acute decompensated heart failure did not reduce IL-6 and NT-proBNP levels.</span></span></span></span></span> Heart failure,Curcumin,Cardiovascular Diseases, 609 614 http://hehp.modares.ac.ir/browse.php?a_code=A-10-77502-3&slc_lang=en&sid=4